Back to top

Analyst Blog

Pharmacyclics, Inc. (PCYC - Analyst Report) recently announced that it has initiated an underwritten public offering to sell 2.2 million shares of its common stock. The amount represents approximately 3.1% of the total number of shares outstanding at Pharmacyclics. Pharmacyclics will be responsible for selling all the shares. The company also expects to provide the underwriters with a 30-day over-allotment option for an additional 0.33 million shares.

Pharmacyclics intends to utilize the net proceeds to develop its pipeline including its lead candidate ibrutinib. Pharmacyclics is being co-developed with Janssen Biotech, a Johnson & Johnson (JNJ - Analyst Report) company, for multiple indications.

We remind investors that in 2012 the company received orphan drug and fast track designations in the US for ibrutinib for the treatment of chronic lymphocytic leukemia. The candidate also enjoys orphan drug and fast track designations for the treatment of mantle cell lymphoma.

In Feb 2013, the US Food and Drug Administration (FDA) granted breakthrough therapy designation to ibrutinib for treating MCL patients as a monotherapy. The FDA granted a similar status to ibrutinib for treating patients suffering from Waldenström's macroglobulinemia also as a monotherapy. Both the indications are B-cell malignancies. We expect investors focus to remain on the development of ibrutinib.

Pharmacyclics is also developing candidates for the treatment of non-Hodgkin's lymphoma, refractory follicular lymphoma and multiple myeloma. Most of these candidates are in phase II development.

Pharmacyclics, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Biopharmaceutical stocks, which currently look more attractive, include Array Biopharma (ARRY - Snapshot Report), Celldex Therapeutics, Inc. (CLDX - Snapshot Report). Both stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.55 +11.64%
CHINA BIOLO… CBPO 55.57 +7.40%
BITAUTO HOL… BITA 96.14 +5.58%
LUXOFT HOLD… LXFT 38.77 +3.64%
INSITE VISI… INSV 0.30 +3.41%